ThursdayApr 21, 2022 3:07 pm

Why MindMed’s LSD Trial for Anxiety May Be Important to Psychedelic Investors

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial’s results to be a turning point for the company. LSD (lysergic acid diethylamide) is a potent hallucinogen that is synthetically manufactured from lysergic acid. It’s commonly known as acid, mellow yellow, doses and trips. When ingested in small doses, this hallucinogen produces mild changes in mood, thought and perception. The company has many projects using LSD, including…

Continue Reading

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…

Continue Reading

WednesdayApr 20, 2022 1:30 pm

Study Links Psilocybin Mushrooms to Decreased Risk of Opioid Addiction

The past couple of years have seen a rise in the popularity of alternative medicines. As people become more aware of the risks and side effects associated with the use of pharmaceuticals, interest in safer alternatives has increased exponentially. Psychedelics such as magic mushrooms have enjoyed a lot of public attention as a result. Although research into the potential benefits and risks of psychedelics is just beginning, initial studies have found that they may possess the ability to alleviate anxiety, stress and depression. A study recently published in “Nature” has revealed that psilocybin, a hallucinogenic chemical found in magic mushrooms,…

Continue Reading

WednesdayApr 20, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine Back in October 2021, Delic…

Continue Reading

TuesdayApr 19, 2022 3:26 pm

Legislators in Maryland Advance Psychedelic Research Measure to Governor’s Desk

Last week, legislators in Maryland advanced a measure to the governor that would establish a state fund to provide access to psychedelic drugs such as ketamine, MDMA and psilocybin free of charge to veterans suffering from traumatic brain injury and post-traumatic stress disorder (PTSD). The measure, which was introduced by Sen. Sarah Elfreth, cleared the House the week before. This comes after its unanimous approval in the Senate in March. This bill would establish a traumatic brain injury and PTSD alternative therapies fund. In its text, the bill stipulates that the monies from the fund would be used to study…

Continue Reading

MondayApr 18, 2022 12:31 pm

Machine Learning Model Enables Researchers to Pinpoint PTSD Sufferers

Researchers have designed a machine learning model that can identify individuals suffering from PTSD by conducting an analysis of text data with 80% accuracy. Post-traumatic stress disorder (PTSD) is a mental health condition that is triggered by a traumatic event which an individual may witness or experience. This machine learning model may, in the future, be used as an inexpensive and accessible screening method to help physicians detect and diagnose post-traumatic stress disorder or other mental conditions, via telehealth platforms. Jeff Sawalha, a PhD candidate specializing in psychiatry at the University of Alberta, led this project. He carried out an…

Continue Reading

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

Continue Reading

MondayApr 18, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Continues Expansion to Make Science-Backed Psychedelic Medicines Accessible to Patients with Mental Health Conditions

Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression It is also expanding its ability to research novel compounds and develop IP for future commercialization Delic Holdings' (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant…

Continue Reading

ThursdayApr 14, 2022 4:00 pm

Psychedelics Could Help Combat Alcoholism

Recently conducted studies have found that psychedelics may be useful in the treatment of various mental conditions, including anxiety, depression and alcoholism. “Psychedelic” is a term coined by Dr. Humphry Osmond in the 20th century. Osmond, who specialized in psychiatry, theorized that some mental illnesses were brought about by chemical imbalances in the brain. Through his research in the ‘50s, he discovered that these hallucinogenic substances could be used to treat alcoholism. Alcoholism, or alcohol-use disorder, is defined as an addiction to drinking alcohol. The disorder develops as an individual drinks so much alcohol that their body becomes dependent on…

Continue Reading

WednesdayApr 13, 2022 2:52 pm

New Study Highlights How Sleep Patterns Are Impacted by Psilocybin

A new study has found that psilocybin causes temporary changes to the basic structural organization of normal sleep in lab mice. Professor Vladyslav V. Vyazovskiy of the University of Oxford, who conducted the study, stated that evidence had shown that psychedelics such as psilocybin could rapidly reduce core symptoms of various psychiatric conditions, even in serious cases that were resistant to other treatments. The researchers’ objective was to examine the potential impact that psilocybin had on sleep, as sleep disturbance contributed to the continuation as well as the onset of diverse mental illnesses. For their study, the researchers used animal…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050